SCHEMBL6542128

SCHEMBL6542128

Nc1nc(C(=NOC(c2ccccc2)(c2ccccc2)c2ccccc2)C(=O)N[C@@H]2C(=O)N3C(C(=O)OC(c4ccccc4)c4ccccc4)=C(Sc4nncs4)CSC23)c(Cl)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNH2 Q12809 1/20 0.39
▸ TDP1 Q9NUW8 5/20 0.37
▸ NR1I2 O75469 5/20 0.37
▸ KDM4E B2RXH2 4/20 0.37
▸ ALDH1A1 P00352 4/20 0.37
▸ HSD17B10 Q99714 4/20 0.37
▸ MAPT P10636 4/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ HPGD P15428 2/20 0.37
▸ CYP3A4 P08684 2/20 0.37
▸ CYP2C9 P11712 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ ESR1 P03372 2/20 0.37
▸ PPARG P37231 2/20 0.37
▸ ADORA3 P0DMS8 1/20 0.37
▸ SLC15A2 Q16348 1/20 0.37
▸ CTDSP1 Q9GZU7 1/20 0.37
▸ HIF1A Q16665 1/20 0.37
▸ PGR P06401 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6542123 1.00 KCNH2 (0.39) KCNH2TDP1NR1I2KDM4EALDH1A1
SCHEMBL6543086 0.93 KCNH2 (0.39) KCNH2TDP1NR1I2KDM4EALDH1A1
SCHEMBL6543084 0.93 KCNH2 (0.39) KCNH2TDP1NR1I2KDM4EALDH1A1
SCHEMBL14184725 0.90 — —
SCHEMBL3391924 0.90 — —
SCHEMBL14174245 0.90 — —
SCHEMBL6541755 0.89 KCNH2 (0.38) KCNH2TDP1NR1I2KDM4EALDH1A1
SCHEMBL6541751 0.89 KCNH2 (0.38) KCNH2TDP1NR1I2KDM4EALDH1A1
SCHEMBL6543292 0.88 ALDH1A1 (0.37) KCNH2TDP1NR1I2KDM4EALDH1A1
SCHEMBL6543286 0.88 ALDH1A1 (0.37) KCNH2TDP1NR1I2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1333836-A4 CEPHALOSPORIN ANTIBIOTICS AND PRODRUGS THEREOF ESSENTIAL THERAPEUTICS INC (US) 2004-07-07 — — EP disclosed
EP-1333836-A2 CEPHALOSPORIN ANTIBIOTICS AND PRODRUGS THEREOF Essential Therapeutics, Inc. (US) 2003-08-13 — — EP disclosed
US-6599893-B2 Such as (7R)-7-(2-(2-amino-5-chlorothiazol-4-yl)-2-trityl-oxyiminoacetylamino)-3-(4 -methyl-(1,2, 3)thiadiazol-5-ylsulfanyl)-8-oxo-5-thia-1-aza-bicyclo(4.2.0)oct-2-ene-2 -carboxylic acid benzhydryl ester; methicillin-resistance ESSENTIAL THERAPEUTICS, INC. 2003-07-29 — — US disclosed
US-20020115650-A1 Cephalosporin antibiotics and prodrugs thereof MICROCIDE PHARMACEUTICALS. 2002-08-22 — — US disclosed
WO-2002017854-A2 CEPHALOSPORIN ANTIBIOTICS AND PRODRUGS THEREOF ESSENTIAL THERAPEUTICS, INC. (US) 2002-03-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115650-A1 Cephalosporin antibiotics and prodrugs thereof PEPD, ABCG2, ABCC1 KCNH2 2498/4885TDP1 2967/4885NR1I2 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback